Navigation Links
Proteolix Raises $79 Million in Series C Financing
Date:9/8/2008

d-Knight, Ph.D., Managing Director of Nomura Phase4 Ventures.

Carfilzomib is currently in Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. In non- clinical studies, carfilzomib has consistently exhibited a high level of selectivity for a single active site in the proteasome, and the reported clinical data to-date indicate the drug is well tolerated. The company's most advanced clinical trials of carfilzomib are evaluating the compound's activity among multiple myeloma patients who have failed or relapsed following prior therapy. In addition to carfilzomib, Proteolix has generated a rich pipeline, including an oral anti-cancer proteasome inhibitor as well as a selective inhibitor targeting the proteasome in the cells of the immune system.

New Board Member Announced

Proteolix is also pleased to announce that Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals, Inc., has joined its Board of Directors. Mr. Hastings brings more than 20 years of biotechnology and pharmaceutical industry experience as a senior-level executive in public and private companies. "Proteolix has made great progress in advancing its lead cancer therapeutic through clinical trials and developing an earlier stage pipeline of proteasome inhibitors," said Mr. Hastings on behalf of Proteolix's Board of Directors. "I personally look forward to working closely with the team on their continued success."

Mr. Hastings also serves on the board of directors of Cerimon Pharmaceuticals, Inc. and serves as a director of the Biotechnology Industry Organization (BIO) and BayBIO.

About Proteolix

Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib (PR-171
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Pearl Therapeutics Raises $15.5 Million in Private Financing
4. Enobia Pharma Raises $40.1 Million Series B Financing
5. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
6. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
7. VisEn Medical Raises $7 Million in Series B Financing
8. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
9. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
10. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
11. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015 Psyche Systems Corporation and ... offers a first-of-its-kind platform that helps labs comply with ... results, transforms the way patients engage with these results, ... Health provides a HIPAA-compliant digital platform that gives ... and understand their lab results, and uniquely connects labs, ...
(Date:5/5/2015)... , May 5, 2015  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, has ... independent analysis designed to reflect the healthcare patterns ... This model will be used to characterize the ... could have on those groups of patients and ...
(Date:5/5/2015)... May 5, 2015  A group of biotechnology executives ... Coma Research Institute, a non-profit organization dedicated to providing ... suffering from disorders of consciousness.  ...   ... in which no voluntary actions can be initiated by ...
(Date:5/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services ... Global Version" report to their offering. ... of molecular diagnostics and pharmacogenics hold the promise ... that is moving out of the national and ...
Breaking Biology Technology:Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... - Company to Host Conference Call at 4:30 p.m. ET ... PCYC ) today reported financial results for its fourth ... for the fourth quarter of,fiscal 2008 was $4.6 million, or ... or $0.27 per share, for the fourth quarter of fiscal ...
... is accelerating improvements for converting plant biomass into biofuelas ... needs, reports Eddy Rubin, Director of the U.S. Department ... August 14 edition of the journal Nature . ... a path forward for how emerging genomic technologies will ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced that ... leading proxy advisory firms, have,recommended that SGX stockholders vote ... LLY ) at the SGX Special Stockholders Meeting,scheduled ... The Board of Directors of SGX unanimously recommends ...
Cached Biology Technology:Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 2Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 3Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 4Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 6DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 2DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 3DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 4SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 2SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 3SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 4
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
(Date:4/1/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces the second shipment of ... to early access pre-order customers. Feedback ... outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop & ... at all outlets and very easy to use. Several ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... has uncovered a protein that plays a vital role in ... in improving the production and quality of crops and biofuels. ... PNAS . The team included researchers from Dartmouth, ... Plant roots use their endodermis, or inner skin, as a ...
... Frederick will present new research at the 108th Annual ... and women,s beliefs about who should pay for dates ... expenses. The paper, Who Pays for Dates? Following versus ... than 17,000 participants; a quarter of whom also provided ...
... Vision licensee, Theresa Ayers , has added a second location ... Ronald Ayers , the husband-and-wife team assumed ownership last month ... Theresa Ayers has been with Pearle Vision, one of ... for more than three decades. She began her career working for ...
Cached Biology News:Research on which gender pays for dates shows change and resistance from convention 2Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 2Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 3Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 4Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 5
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: